Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis

Journal:

Journal of Hepatology

Published:

2025-09-28

DOI:

10.1016/j.jhep.2025.09.016

Affiliations:

21

Authors:

23

Go to article

Institutions	Authors	Share
Pliant Therapeutics, Inc., United States of America (USA)	6.000000	0.26
Hospital of the University of Montreal (CHUM), Canada	1.000000	0.04
King's College Hospital NHS Foundation Trust, United Kingdom (UK)	1.000000	0.04
University of California, Davis (UC Davis), United States of America (USA)	1.000000	0.04
Medical University of Vienna (MUW), Austria	1.000000	0.04
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)	1.000000	0.04
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	1.000000	0.04
UCL, United Kingdom (UK)	1.000000	0.04
Aspen Woods Clinic, Canada	1.000000	0.04
Stanford University, United States of America (USA)	1.000000	0.04
The University of Chicago Medicine, United States of America (USA)	1.000000	0.04
University of Miami Health System (UHealth), United States of America (USA)	1.000000	0.04
Toronto General Hospital (TGH), U of T, Canada	1.000000	0.04
University of Alberta (U of A), Canada	1.000000	0.04
McGill University Health Centre (MUHC), Canada	1.000000	0.04
UCSF Health, United States of America (USA)	1.000000	0.04
NIHR Birmingham Biomedical Research Centre, United Kingdom (UK)	0.500000	0.02
Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02
Liver Institute Northwest, United States of America (USA)	0.500000	0.02
Washington State University (WSU), United States of America (USA)	0.500000	0.02

Interested in Clinical Sciences?